The document contains a comprehensive set of amendments aimed at simplifying the EU AI Act’s implementation, improving proportionality for SMEs/SMCs, reinforcing AI Office powers, prohibiting harmful AI misuse (like sexual deepfakes), clarifying conformity assessments, enabling real‑world testing, and aligning AI rules with sector‑specific safety legislation.
News & Trends
Procurar
Recentes
- Commission publishes guidelines on transparency obligations for providers and deployers of certain AI systems
- MDCG Position Paper: UDI assignment between manufacturers and distributors
- EMA Questions & answers on Article 31 non-pharmacovigilance referral procedures
- EXTENSION OF THE MDR TRANSITIONAL PERIOD AND REMOVAL OF THE ‘SELL OFF’ PERIODS
- MHRA Updated guidance for the International Recognition Procedure (IRP)
- MDCG 2021-5 Rev. 1 .Guidance on standardisation for medical devices
- Qualification of novel methodologies (QoNM) for medicinal product development . Procedural Guidance to applicants
- FDA Guidance for Drug Development